Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New treatment options in intermittent claudication: the US experience
Autore:
Hiatt, WR;
Indirizzi:
Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA Univ Colorado Denver COUSA 80202 ado, Hlth Sci Ctr, Denver, CO 80202 USA
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
, , anno: 2001, supplemento:, 119
pagine: 20 - 27
SICI:
1368-5031(200104):<20:NTOIIC>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERIPHERAL VASCULAR-DISEASE; OCCLUSIVE ARTERIAL-DISEASE; PROPIONYL-L-CARNITINE; DOUBLE-BLIND TRIAL; QUALITY-OF-LIFE; PENTOXIFYLLINE EFFICACY; MULTICENTER TRIAL; WALKING DISTANCE; LIMB ISCHEMIA; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
59
Recensione:
Indirizzi per estratti:
Indirizzo: Hiatt, WR Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA Univ ColoradoDenver CO USA 80202 Sci Ctr, Denver, CO 80202 USA
Citazione:
W.R. Hiatt, "New treatment options in intermittent claudication: the US experience", INT J CL PR, 2001, pp. 20-27

Abstract

The goals of treatment in intermittent claudication are to modify cardiovascular risk factors and to reduce claudication pain, increase walking distance and improve qualify of life. Walking distance in intermittent claudication can be improved both by exercise rehabilitation and by pharmacological treatments. At present, the only two drugs licensed in the US for the treatment of claudication symptoms are oxpentifylline and cilostazol. Although oxpentifylline has been shown to increase maximal and pain-free walking distance in a number of trials, other studies call its efficacy into question. Eight double-blind, placebo-controlled trials have established that cilostazol improves both maximal and pain-free walking distance in patients with moderate to severe intermittent claudication, with highly statistically significant differences compared with placebo. Cilostazol has also been shown to improve the physical dimensions of qualify of life. Naftidrofuryl is licensed for the treatment of intermittent claudication in Europe, but not in the US. Some clinical trials have shown it to be effective in treating intermittent claudication. Promising new agents in the treatment of intermittentclaudication include L-arginine, propionyl-L-carnitine, prostaglandins, and angiogenic growth factors such as vascular endothelial growth factor and basic fibroblast growth factor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:25:06